{"id":688364,"date":"2022-09-23T07:22:57","date_gmt":"2022-09-23T11:22:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/"},"modified":"2022-09-23T07:22:57","modified_gmt":"2022-09-23T11:22:57","slug":"tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/","title":{"rendered":"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Sept.  23, 2022  (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 75,000 common shares at $0.83 per share, bringing his total holding to 175,000 common shares.<\/p>\n<p align=\"justify\">\n        <strong>About Tiziana Life Sciences<\/strong><br \/>\n        <br \/>Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana\u2019s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana\u2019s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana\u2019s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.<\/p>\n<p align=\"justify\">\n        <strong>For further inquiries:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Tiziana Life Sciences Ltd<br \/><\/strong><br \/>\n            <br \/>Hana Malik, Business Development, and Investor Relations Manager \u00a0<br \/>+44 (0) 207 495 2379<br \/>email:\u00a0<a href=\"mailto:info@tizianalifesciences.com\" rel=\"nofollow noopener\" target=\"_blank\">info@tizianalifesciences.com<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Investors:<\/strong><br \/>\n            <br \/>Irina Koffler<br \/>LifeSci Advisors, LLC<br \/>646.970.4681<br \/><a href=\"mailto:ikoffler@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">ikoffler@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OGQyYjczNzUtOTUzMS00ZDhkLTkxNDYtYmIxNDNiODY2MjllLTExMzU0NTY=\/tiny\/Tiziana-Life-Sciences-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 75,000 common shares at $0.83 per share, bringing his total holding to 175,000 common shares. About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana\u2019s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana\u2019s two lead candidates, intranasal &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688364","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 75,000 common shares at $0.83 per share, bringing his total holding to 175,000 common shares. About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana\u2019s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana\u2019s two lead candidates, intranasal &hellip; Continue reading &quot;Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-23T11:22:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer\",\"datePublished\":\"2022-09-23T11:22:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/\"},\"wordCount\":208,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/\",\"name\":\"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=\",\"datePublished\":\"2022-09-23T11:22:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/","og_locale":"en_US","og_type":"article","og_title":"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer - Market Newsdesk","og_description":"NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (\u201cTiziana\u201d or the \u201cCompany\u201d), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 75,000 common shares at $0.83 per share, bringing his total holding to 175,000 common shares. About Tiziana Life Sciences Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana\u2019s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana\u2019s two lead candidates, intranasal &hellip; Continue reading \"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-23T11:22:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer","datePublished":"2022-09-23T11:22:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/"},"wordCount":208,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/","name":"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=","datePublished":"2022-09-23T11:22:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjE3MSM1MTY4NTE0IzIxMjM4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-announces-purchase-of-common-shares-by-chief-medical-officer-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688364"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688364\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688364"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688364"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}